Confidence in the biopharmaceutical industry has climbed to its highest point since 2022, signalling a sector that is regaining momentum despite persistent regulatory and market pressures. The rebound reflects the impact of strategic restructuring, disciplined capital allocation, and renewed investment in innovation. As dealmaking accelerates and funding sentiment improves, the industry appears increasingly positioned to convert scientific progress into sustainable growth, according to GlobalData, a leading intelligence and productivity platform
GlobalData’s State of the Biopharmaceutical Industry 2026 (Mid-Year Update) reveals that 55% of the 157 pharmaceutical professionals surveyed* feel optimistic or very optimistic about industry growth over the next 12 months, a meaningful recovery from the 2023 trough of 46% and up 10% from six months ago. Only 10% feel pessimistic.
Hannah Hans, Head of Pharma Strategic Intelligence at GlobalData, comments: “What makes this recovery noteworthy is what is driving it. This is not a story of improved external conditions. The US tariffs, Most Favored Nation (MFN) pricing reform, Inflation Reduction Act (IRA)-related drug price negotiations and the looming patent cliff have not gone away. It is a story of an industry that absorbed significant disruption, made challenging decisions, and reprioritised.”
Companies restructured cost bases, sharpened their development priorities and engaged directly with policymakers rather than waiting for certainty that was never going to arrive. By early 2026, that discipline had translated into something more valuable than optimism: the ability to plan.
Hans adds: “Companies did not just wait for conditions to improve; strategic and focused choices were made. The optimism we are seeing now is grounded in that, and that makes it more credible.”
The deal market is now reflecting that internal conviction. Q1 2026 M&A deal value rose 71% year over year and the IPO market has reopened sharply, with activity up 210%. Biotech funding optimism has followed, with 52% of respondents in the survey done by GlobalData now optimistic about recovery over the next 12 months, up from 39% in December 2025.
Hans continues: “Deal activity at this level is always telling. When companies are willing to commit capital at scale, it means they have done the work internally and like what they see. The science in cardiometabolic, oncology and neurology is genuinely compelling right now, and the market is pricing that in.”
Headwinds such as US tariffs and government actions are the most negative trend, with 69% of survey respondents naming them as the biggest policy concern facing the industry, and European respondents feeling this most acutely at 78%. The patent cliff will intensify pressure through the decade. These are structural forces that will define strategy for years.
Hans concludes: “The recovery is real, and the pipeline backs it up. We have not seen this depth of high-value clinical catalysts across therapy areas at the same time in years. The leaders in this space are not waiting for the external environment to improve, as they continue to build out pipelines, secure assets and see their potential in multiple indications. That is not sentiment, that is science combined with strategic discipline.”
*GlobalData’s survey, which was fielded from 20 March to 20 April 2026, included a total of 157 GlobalData biopharmaceutical clients and prospects.
